Wanbury Ltd

Wanbury has recently experienced a revision in its score by MarketsMOJO, reflecting changes in its market evaluation. Despite a recent decline in stock performance, the company has demonstrated significant growth over the past year, outperforming the Sensex and maintaining a position above key moving averages.

Wanbury has recently experienced a revision in its stock evaluation, reflecting its strong market performance. The smallcap pharmaceutical company has outperformed its sector and maintained a consistent upward trend, with impressive returns over the past week. Additionally, Wanbury has been added to MarketsMOJO's list, highlighting its growth potential.

Wanbury has recently experienced a revision in its score, reflecting its strong market performance and upward trend. The stock has been added to MarketsMOJO's list, highlighting its impressive gains and ability to outperform the sector. Investors are closely monitoring Wanbury's continued growth potential in the pharmaceutical industry.

Wanbury has recently experienced a revision in its stock evaluation, reflecting its strong market performance. The pharmaceutical company has outperformed its sector and demonstrated significant gains over the past week. Additionally, Wanbury has been added to MarketsMOJO's list, highlighting its potential for continued growth in the smallcap segment.

Wanbury has recently experienced a revision in its stock evaluation, reflecting its impressive performance in the market. The company has been added to MarketsMOJO's list, highlighting its significant growth and consistent upward trend. With a notable increase in returns, Wanbury continues to stand out in the pharmaceutical sector. Wanbury, a microcap pharmaceutical firm, has captured attention as its stock price reached a 52-week high, trading at Rs. 306.75. The stock has outperformed its sector and demonstrated a remarkable rise over the past few days, with a notable increase in returns. Currently trading above its various moving averages, Wanbury's performance indicates a positive trajectory. In comparison to the Sensex, which has shown a solid performance, Wanbury's growth over the past year has been exceptional, showcasing its potential in the market. Despite the current 'Sell' call from MarketsMOJO, the company's recent achievements and upward momentum make it a noteworthy player in the pharmaceutical industry.

Wanbury has recently been added to MarketsMOJO's list following a revision in its score, reflecting the stock's impressive performance. The microcap pharmaceutical company has outperformed its sector and demonstrated significant growth, trading above key moving averages and achieving a remarkable increase compared to the Sensex over the past year.

Wanbury has recently experienced a notable adjustment in its evaluation, reflecting its strong market performance and significant price increase. The stock has been added to MarketsMOJO's list, highlighting its impressive growth metrics, including a remarkable one-year performance compared to the broader market. Investors are advised to remain cautious amid market volatility.

Wanbury has recently experienced a revision in its stock evaluation, reflecting its strong performance in the pharmaceutical sector. The stock has shown remarkable growth over the past year, significantly outperforming the broader market. Additionally, Wanbury has been added to MarketsMOJO's list, indicating increased attention from analysts.

Wanbury, a microcap pharmaceutical company, reported a negative performance in the second quarter of fiscal year 2024-2025. Despite a positive trend in net sales and near-term sales, the company's interest cost and profit after tax have increased and decreased respectively. Increased borrowing and slowed debtors turnover may lead to a stressed liquidity situation.

Wanbury, a microcap pharmaceutical company, has seen a significant increase in its stock price, reaching a 52-week high on September 23, 2024. The company's stock has been on an upward trend for the past three days, with a consecutive gain of 13.32%. According to MarketsMOJO, the current stock call for Wanbury is 'Hold', with the company's stock trading higher than its moving averages. Wanbury's impressive performance in the past year, with a 355.09% increase in its stock price, showcases its strong potential and growth in the pharmaceutical industry. The company's focus on producing high-quality and affordable medicines has made it a trusted name in the market.

Wanbury, a microcap pharmaceutical company, has gained attention in the stock market with its stock price reaching an all-time high of Rs. 291 on September 23, 2024. The company's stock has outperformed the sector by 3.18% and is currently trading above its moving averages. With a strong presence in the thriving pharmaceutical industry, Wanbury has shown impressive growth and potential for future success.

Wanbury, a microcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high of Rs. 291 on September 23, 2024. The company's stock has outperformed the sector by 3.18% and has been on a consecutive gain for the last three days. With a 349.08% increase in the past year, Wanbury showcases strong potential and growth in the pharmaceutical industry.

Wanbury, a microcap pharmaceutical company, has been in the spotlight as its stock price reached a 52-week high on September 20, 2024. The stock has shown a consecutive gain for the last two days and a rise of 8.13%. According to MarketsMOJO, the stock is currently rated as 'Hold' and has outperformed the sector by 2.73%. With a strong upward trend and impressive growth in the past year, Wanbury is a promising player in the pharmaceutical industry.

Wanbury, a microcap pharmaceutical company, has seen a significant increase in its stock price, reaching an all-time high of Rs.275 on September 20, 2024. The company's stock has been gaining for the past two days, outperforming the sector by 2.22%. Wanbury's impressive performance in the past year and positive trend indicate potential for growth in the pharmaceutical industry.

Wanbury, a microcap pharmaceutical company, has been in the spotlight as its stock price reached a 52-week high on September 16, 2024. The stock is currently trading at Rs.270 and has outperformed its sector by 1.95%. With a 'Hold' rating from MarketsMOJO, Wanbury's recent performance has been impressive, gaining 12.99% in the last 3 days. The stock is also trading above its moving averages, indicating a positive trend. Wanbury's stock has shown a remarkable growth of 336.51% in the past year, outperforming the market. With its focus on the healthcare industry, Wanbury is a company to watch out for in the stock market.

Wanbury, a microcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high on September 16, 2024. With a 14.82% increase in just three days and a positive trend in its stock price, Wanbury's performance has been impressive. However, this article does not offer any recommendations or mention future potential.

Wanbury, a microcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high on September 15, 2024. With a 'Hold' rating from MarketsMOJO, the stock has outperformed the sector by 4.96% and gained 10.8% in the last two days. Wanbury's strong performance and focus on producing affordable medicines make it a promising player in the pharmaceutical industry.

Wanbury, a microcap pharmaceutical company, has seen a significant increase in its stock price, reaching an all-time high on September 14, 2024. The company's stock has been performing well, outperforming the sector by 4.96% today and showing a 10.8% increase in the last two days. With a 'Hold' rating from MarketsMOJO, Wanbury's stock has been trading higher than its moving averages and has shown a remarkable 346.99% growth in the past year, highlighting its potential in the pharmaceutical industry. The company's focus on producing affordable and high-quality medicines, along with its commitment to innovation and research, has contributed to its success.

Wanbury, a microcap pharmaceutical company, has been performing well in the market, with its stock reaching a 52-week high on September 13th, 2024. The stock has shown consecutive gains in the past two days, with a 9.29% increase in returns. Wanbury's strong presence in the pharmaceutical industry has contributed to its remarkable 342.44% growth in the past year.